Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGENNASDAQ:LXRXNASDAQ:VNDANASDAQ:XOMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$3.38-3.4%$2.17$1.38▼$19.69$71.56M1.48582,423 shs771,010 shsLXRXLexicon Pharmaceuticals$0.63-6.5%$0.52$0.28▼$2.45$227.74M1.076.50 million shs4.92 million shsVNDAVanda Pharmaceuticals$3.98-1.2%$4.50$3.85▼$6.75$234.56M0.69726,135 shs623,328 shsXOMAXOMA$27.49+10.9%$21.66$18.35▼$35.00$328.59M0.8928,428 shs35,367 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus-3.43%+13.61%+98.82%-2.31%-69.52%LXRXLexicon Pharmaceuticals-6.51%-3.95%+23.09%-9.35%-66.31%VNDAVanda Pharmaceuticals-1.24%-8.92%-3.63%-16.21%-21.19%XOMAXOMA+10.89%+19.31%+37.66%+1.44%+6.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGENAgenus3.9133 of 5 stars3.12.00.04.63.01.70.6LXRXLexicon Pharmaceuticals3.2136 of 5 stars4.24.00.00.01.81.70.6VNDAVanda Pharmaceuticals4.2112 of 5 stars3.51.00.04.22.03.31.3XOMAXOMA4.1298 of 5 stars3.52.00.03.03.03.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGENAgenus 2.17Hold$9.00166.27% UpsideLXRXLexicon Pharmaceuticals 2.40Hold$3.67482.01% UpsideVNDAVanda Pharmaceuticals 3.00Buy$16.50314.57% UpsideXOMAXOMA 3.00Buy$69.50152.82% UpsideCurrent Analyst Ratings BreakdownLatest AGEN, XOMA, LXRX, and VNDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/13/2025AGENAgenusRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$3.00 ➝ $4.005/7/2025VNDAVanda PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/30/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/21/2025AGENAgenusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/17/2025XOMAXOMABenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.004/1/2025VNDAVanda PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/28/2025LXRXLexicon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/28/2025XOMAXOMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$104.00 ➝ $104.003/19/2025XOMAXOMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$104.00 ➝ $104.003/18/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGENAgenus$103.46M0.69N/AN/A($7.78) per share-0.43LXRXLexicon Pharmaceuticals$31.08M7.33N/AN/A$0.38 per share1.66VNDAVanda Pharmaceuticals$198.77M1.18N/AN/A$9.23 per share0.43XOMAXOMA$10.22M32.15N/AN/A$7.72 per share3.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGENAgenus-$245.76M-$10.68N/AN/AN/A-145.89%N/A-85.68%N/ALXRXLexicon Pharmaceuticals-$177.12M-$0.64N/AN/AN/A-4,109.41%-107.38%-64.09%N/AVNDAVanda Pharmaceuticals-$18.90M-$0.75N/AN/AN/A-9.51%-3.49%-2.90%7/30/2025 (Estimated)XOMAXOMA-$40.83M-$2.07N/AN/AN/A-151.34%-24.95%-9.64%N/ALatest AGEN, XOMA, LXRX, and VNDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025LXRXLexicon Pharmaceuticals-$0.10-$0.07+$0.03-$0.07$1.26 million$1.26 million5/12/2025Q1 2025AGENAgenus-$1.61-$1.03+$0.58-$1.03$26.38 million$24.07 million5/7/2025Q1 2025VNDAVanda Pharmaceuticals-$0.55-$0.50+$0.05-$0.50$45.13 million$50.04 million3/17/2025Q4 2024XOMAXOMA-$0.29-$0.46-$0.17-$0.46$8.75 million$8.70 million3/11/2025Q4 2024AGENAgenus-$2.36-$2.04+$0.32-$2.04$30.09 million$26.84 million3/6/2025Q4 2024LXRXLexicon Pharmaceuticals-$0.11-$0.09+$0.02-$0.09$6.48 million$26.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGENAgenusN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/AVNDAVanda PharmaceuticalsN/AN/AN/AN/AN/AXOMAXOMAN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGENAgenusN/A0.190.19LXRXLexicon Pharmaceuticals0.567.457.43VNDAVanda PharmaceuticalsN/A4.394.37XOMAXOMA1.287.527.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGENAgenus61.46%LXRXLexicon Pharmaceuticals74.70%VNDAVanda Pharmaceuticals88.14%XOMAXOMA95.92%Insider OwnershipCompanyInsider OwnershipAGENAgenus4.60%LXRXLexicon Pharmaceuticals6.80%VNDAVanda Pharmaceuticals10.00%XOMAXOMA9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGENAgenus44021.17 million22.38 millionOptionableLXRXLexicon Pharmaceuticals140361.49 million229.49 millionOptionableVNDAVanda Pharmaceuticals29058.93 million53.13 millionOptionableXOMAXOMA1011.95 million10.94 millionOptionableAGEN, XOMA, LXRX, and VNDA HeadlinesRecent News About These CompaniesXOMA Royalty Reports Strong Q1 2025 ResultsMay 14 at 12:25 AM | tipranks.comXOMA Royalty: Q1 Earnings SnapshotMay 13 at 7:40 PM | sfgate.comXOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business AchievementsMay 13 at 7:40 PM | finance.yahoo.comXOMA Royalty (XOMA) Tops Q1 Earnings and Revenue EstimatesMay 13 at 9:50 AM | zacks.comXOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual ConferenceMay 7, 2025 | globenewswire.comXOMA (XOMA) Expected to Announce Quarterly Earnings on ThursdayMay 3, 2025 | marketbeat.comHigh Growth Tech Stocks In The US To Watch April 2025April 22, 2025 | uk.finance.yahoo.comXOMA (NASDAQ:XOMA) Now Covered by BenchmarkApril 19, 2025 | marketbeat.comBenchmark Initiates Coverage of XOMA Royalty Corporation - Preferred Stock (XOMAP) with Buy RecommendationApril 18, 2025 | msn.comXoma initiated with a Buy at BenchmarkApril 17, 2025 | markets.businessinsider.comXoma (XOMA) Receives Buy Rating from Benchmark with Promising Growth Forecast | XOMA Stock NewsApril 17, 2025 | gurufocus.comXOMA Royalty Completes Sale of Kinnate Pipeline AssetsApril 14, 2025 | gurufocus.comXOMA (XOMA) Sells Kinnate Biopharma Pipeline Assets for Potential $270M | XOMA Stock NewsApril 14, 2025 | gurufocus.comXOMA Royalty Completes Sale of Kinnate Pipeline Assets | XOMA Stock NewsApril 14, 2025 | gurufocus.comXOMA Royalty Completes Sale of Kinnate Pipeline AssetsApril 14, 2025 | globenewswire.comInsider Buying: XOMA Co. (NASDAQ:XOMA) CIO Purchases 2,000 Shares of StockApril 10, 2025 | insidertrades.comXOMA Royalty Corporation (XOMA): Among Stocks Insiders Bought in April After Trump’s Tariff RolloutApril 9, 2025 | msn.comJoseph M. Limber Buys 5,243 Shares of XOMA Co. (NASDAQ:XOMA) StockApril 9, 2025 | insidertrades.comBioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3April 8, 2025 | accessnewswire.comXOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech TwistApril 8, 2025 | seekingalpha.comXOMA Royalty to Present at Jones Healthcare and Technology Innovation ConferenceApril 2, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to BenefitDoorDash’s Uptrend Is Gaining Momentum in 2025By Thomas Hughes | May 9, 2025View DoorDash’s Uptrend Is Gaining Momentum in 2025IBM's AI Offensive: Assessing IBM's Path to Renewed GrowthBy Jeffrey Neal Johnson | May 8, 2025View IBM's AI Offensive: Assessing IBM's Path to Renewed GrowthAGEN, XOMA, LXRX, and VNDA Company DescriptionsAgenus NASDAQ:AGEN$3.38 -0.12 (-3.43%) As of 05/13/2025 04:00 PM EasternAgenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Lexicon Pharmaceuticals NASDAQ:LXRX$0.63 -0.04 (-6.51%) As of 05/13/2025 04:00 PM EasternLexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Vanda Pharmaceuticals NASDAQ:VNDA$3.98 -0.05 (-1.24%) As of 05/13/2025 04:00 PM EasternVanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.XOMA NASDAQ:XOMA$27.49 +2.70 (+10.89%) As of 05/13/2025 04:00 PM EasternXOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Stock Surges on Bullish News: How High Could It Climb? NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner? Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long Why Boeing May Be Ready to Take Off After Latest Developments Goldman Sachs Warns of 20% Market Sell-Off: Are They Right? 3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest Loser Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
